| The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) BI Rini, D Battle, RA Figlin, DJ George, H Hammers, T Hutson, E Jonasch, ... Journal for immunotherapy of cancer 7, 1-20, 2019 | 227 | 2019 |
| Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status CD Bergerot, EJ Philip, PG Bergerot, JA Hsu, N Dizman, M Salgia, ... Cancer 127 (3), 354-358, 2021 | 30 | 2021 |
| Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement G Bratslavsky, N Mendhiratta, M Daneshvar, J Brugarolas, MW Ball, ... Cancer 127 (21), 3957-3966, 2021 | 27 | 2021 |
| Fear of cancer recurrence in patients with localized renal cell carcinoma CD Bergerot, D Battle, EJ Philip, PG Bergerot, P Msaouel, AB Smith, ... JCO Oncology Practice 16 (11), e1264-e1271, 2020 | 22 | 2020 |
| COVID-19 and financial toxicity in patients with renal cell carcinoma MD Staehler, DJ Battle, CD Bergerot, SK Pal, DF Penson World journal of urology 39, 2559-2565, 2021 | 17 | 2021 |
| Distress in patients with renal cell carcinoma: a curious gap in knowledge. CD Bergerot, D Battle, MD Staehler, SK Pal BJU international 123 (2), 2019 | 15 | 2019 |
| Counterbalancing COVID-19 with cancer surveillance and therapy: a survey of patients with renal cell carcinoma M Staehler, D Battle, SK Pal, CD Bergerot European urology focus 7 (6), 1355-1362, 2021 | 11 | 2021 |
| Team leadership and cancer end-of-life decision making JM Waldfogel, DJ Battle, M Rosen, L Knight, CB Saiki, SA Nesbit, ... Journal of oncology practice 12 (11), 1135-1140, 2016 | 9 | 2016 |
| Sources of frustration among patients diagnosed with renal cell carcinoma CD Bergerot, D Battle, PG Bergerot, N Dizman, E Jonasch, HJ Hammers, ... Frontiers in Oncology 9, 11, 2019 | 8 | 2019 |
| Patient preferences and expectations of systemic therapy in renal cell carcinoma. D Battle, CD Bergerot, P Msaouel, E Jonasch, T Zhang, DJ George, ... Journal of Clinical Oncology 38 (15_suppl), 5083-5083, 2020 | 7 | 2020 |
| Patient advocates collaborate to ensure patients are members of their own oncology care teams L Lederman, D Madden, D Battle, HK Connolly, ML Smith Journal of oncology practice 12 (11), 980-982, 2016 | 7 | 2016 |
| Patient-reported outcomes on treatment-related side effects in renal cell carcinoma D Battle, WK Rathmell, E Jonasch, P Msaouel, AP Stern, T Zhang, ... JCO 38 (6_suppl), 654, 2020 | 6 | 2020 |
| Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma. M Staehler, D Battle, A Bex, H Hammers, D George European Urology 74 (6), 842-843, 2018 | 6 | 2018 |
| Patients perspectives on adjuvant therapy in renal cell carcinoma D Battle, E Jonasch, HJ Hammers, I Derweesh, DJ George, A Bex, ... J Clin Oncol 36 (Suppl 6), 644, 2018 | 5 | 2018 |
| Patient perceptions of benefits and risks of adjuvant therapy in renal cell carcinoma. D Battle, P Msaouel, SM Pal, UN Vaishampayan, MD Staehler Journal of Clinical Oncology 41 (6_suppl), 663-663, 2023 | 3 | 2023 |
| Addressing resistance to PD-1/PD-(L) 1 pathway inhibition: considerations for combinatorial clinical trial designs T Zhang, PM Forde, RJ Sullivan, E Sharon, E Barksdale, W Selig, ... Journal for immunotherapy of cancer 11 (5), 2023 | 2 | 2023 |
| Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study ME Allaf, SE Kim, V Master, DF McDermott, LC Harshman, SM Cole, ... The Lancet Oncology, 2024 | 1 | 2024 |
| Patient priorities and expectations of systemic therapy in metastatic renal cell carcinoma. D Battle, UN Vaishampayan, P Msaouel, SK Pal, T Zhang, MD Staehler Journal of Clinical Oncology 41 (16_suppl), 4560-4560, 2023 | 1 | 2023 |
| Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy. MD Staehler, H Ebrahimi, UN Vaishampayan, S Rodler, SM Pal, D Battle Journal of Clinical Oncology 41 (6_suppl), 651-651, 2023 | 1 | 2023 |
| Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy. D Battle, CD Bergerot, P Msaouel, T Zhang, DJ George, MD Staehler Journal of Clinical Oncology 38 (15_suppl), 5084-5084, 2020 | 1 | 2020 |
